Resonate Blends, Inc (KOAN) Fair Value & Analysis
Healthcare · US · Market cap $277K
Resonate Blends, Inc
KOAN · US
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.0200 to $0.0010 (−95.0%) since Jun 24, 2026. Share price −20.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0009 – $0.0250 · fair‑value band $0.0010 – $0.0010 · the $0.0010 price screens above the $0.0010 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Resonate Blends, Inc (KOAN) currently trades at $0.0010, while our model-based Fair Value estimate is $0.0010 — implying the stock looks roughly 0.4% overvalued today. We read business quality at 21/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Resonate Blends, Inc generated revenue of $2.2M at a net margin of 51.2%. Net debt stands at $5.3M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Resonate Blends, Inc. engages in the discovery, development, and marketing of products for mankind in the field of regenerative medicine. It focuses on marketing licensed patent-pending natural stem cell mobilizing agents for enhancing individual's ability to mobilize their own adult stem cells from their bone marrow. The company also has a license to market a dual acting all-natural diet aid to help control hunger through normal body signals to the brain and stomach. In addition, it is involved in the research and development activities focusing on exploring other areas, such as Secretogues to enhance a person's own growth hormone production and similar natural bioactive formulations to enhance human performance utilizing known body mechanisms without the use of drugs. The company is based in North Bergen, New Jersey.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Resonate Blends, Inc reported revenue of $1.7M in FY2025 versus $27.0K in FY2021, a compound +181.7%/yr. Reported net income was −$1.7M in FY2025.
Is KOAN fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Resonate Blends, Inc (KOAN) undervalued?
What is the fair value of KOAN?
What is the quality score of KOAN?
What is the revenue of Resonate Blends, Inc (KOAN)?
What is the net profit margin of KOAN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.